The more I read this, the more I think Origin isn’t going to do anything with Bioamber. They are already receiving scrutiny by the SEC on the merger with Artius, throwing Bioamber into the mix will only delay it further. I hope you are right, but it doesn’t seem like the timing is right to do a major transaction.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.